在心力衰竭中的交感调节与高与正常的射出分数.
Karl Fengler1, Karl-Patrik Kresoja1, Karl-Philipp Rommel1
1Department of Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany.
Structural heart : the journal of the Heart Team
|June 8, 2023
概括
脏缺血 (RDN) 显示出心力衰竭与保存喷射率 (HFpEF) 的承诺,在高喷射率 (HEF) 和正常喷射率 (NEF) 组中观察到明显的影响. 对HFpEF的交感调节疗法的进一步研究是有必要的.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 生物医学工程 生物医学工程
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭具有有限的治疗选择和糟糕的结果.
- 糖连接载体2抑制剂在高射出分数 (HEF) HFpEF患者中显示出极小的益处.
- 根据射出分数 (EF) 范围 (HEF与正常EF [NEF]) HFpEF可能涉及不同的生物机械和细胞表型.
研究的目的:
- 在HEF和NEF组中研究不同的HFpEF表型,使用非侵入性单击估计.
- 在HEF和NEF HFpEF患者中,评估脏缩 (RDN) 后压力-体积关系的变化.
主要方法:
- 从先前的RDN研究中将HFpEF患者分为HEF (>60% EF) 和NEF (50% - 60% EF) 组.
- 使用单击估计来推导动脉弹性 (Ea),末缩弹性 (Ees) 和透缩容量 (VPED20).
主要成果:
- 动脉弹性 (Ea) 在两组之间是相似的,并且在RDN后降低.
- 在HEF与NEF相比,末缩弹性 (Ees) 较高,腹缩容量 (VPED20) 较低.
- 在HEF中,Ees和VPED20在RDN后发生了显著的变化,但不是NEF;在RDN后的NEF中,Ees/Ea增加了,但不是HEF.
结论:
- 脏缺血 (RDN) 在NEF和HEF HFpEF患者群体中都表现出有益的影响.
- 这些发现支持对HFpEF的交感调节疗法的进一步研究.
- 不同的HFpEF表型可能对干预有不同的反应,需要量身定制的治疗方法.
相关概念视频
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
01:17Pathophysiology of Heart Failure
1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
470
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
470
01:30Heart Failure IV: Classification and Diagnostic Evaluation
21
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
21
01:22Heart Failure Drugs: β-Blockers
392
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
392